Friday, 17 Nov 2017

You are here

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

The CALM study was multicenter, open-label, randomised, controlled phase 3 study, in adults with active endoscopic Crohn's disease (Crohn's Disease Endoscopic Index of Severity [CDEIS] >6 and a Crohn's Disease Activity Index (CDAI) of 150–450 in patients who were DMARD and biologic naive.

Patients were randomized 1:1 ratio to either tight control or clinical management groups. After 8 weeks of prednisone induction therapy, treatment was escalated in a stepwise manner, from adalimumab induction followed by adalimumab every other week, adalimumab every week, and lastly to both weekly adalimumab and daily azathioprine.

The primary endpoint was mucosal healing (CDEIS <4) with absence of deep ulcers 48 weeks after randomisation. 

Dose escalation was different between groups. The Tight Control group used mulitiple definitions of failure (fecal calprotectin ≥250 μg/g, C-reactive protein ≥5mg/L, CDAI ≥150, or prednisone use), while the clinical management group only used changes in the CDAI or prednisone use.

A total of  244 patients were enrolled w/ a mean disease duration < 1 year. Significantly more Tight Control patients achieved the primary endpoint at week 48 (46%) compared to those with usual care (30%) (p=0·010).

There were no unexpected adverse events which were balanced between groups; and there were no treatment-related deaths. Dropouts were equal between groups (24-26%), mostly due to adverse events.

CALM is the first study to show that timely escalation, using an advanced tight control strategy, can lead to clinical and endoscopic outcomes than symptom-driven decisions alone. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).

Adalimumab Biosimilars Adding Up

Reuters reports that yet another adalimumab biosimilar has been approved by European Union regulators.

The new drug is named Imraldi, and is manufactured by Samsung Bioepis, a company who has several biosimilars approved or in development for worldwide use.

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.  

Uveitis Events Reduced with Select TNF Inhibitors

Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor may reduce the rates of anterior uveitis. A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab and infliximab offer better protection against AU than etanercept.